The resignation of the incumbent president is related to a change in career plans. Board members also elected Cristiano Costanzo to the position of vice president and Piotr Debski to the position of treasurer, who will replace in this place Michal Čuha, who is leaving the Board also due to a change in career plans. The changes take effect on Jan. 1, 2025, and the term of the Board in this composition expires in June 2025.
Phil Krzyzek is managing director at Merck Ltd. He is an experienced and successful commercial healthcare expert with nearly 30 years of experience in pharmaceuticals, CSOs and patient healthcare. He has held senior positions in sales, marketing, business development and general management in a variety of products and services, roles, sectors and types of organizations, from start-ups to blue chips.
Phil Krzyzek, as INFARMA's newly elected CEO, takes the helm at an important time for the industry as Poland's presidency of the EU Council begins. Among other things, it will be marked by further consultations as part of the legislative process for the first review of EU pharmaceutical legislation in 20 years, which will affect the development of and access to innovative therapies for decades to c...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
